PDF(Pubmed)
Abstract：
UNASSIGNED: Human infections caused by Candida albicans are common and range in severity from relatively treatable skin and mucosal conditions to systemic, fatal invasive candidiasis. The treatment of fungal infections is challenged by major obstacles, including the scarcity of effective therapeutic options, the toxicity of available medications, and the escalating antifungal resistance. Hence, there exists an urgent need to develop new classes of antimicrobial agents. This study was conducted to investigate the effect of KW-23 peptide against standard and resistant strains of C. albicans alone and in combination with fluconazole.
UNASSIGNED: A conjugated ultrashort antimicrobial peptide (KW-23) was designed and synthesized. KW-23 was challenged against standard and multidrug-resistant C. albicans alone and in combination with fluconazole using standard antimicrobial and checkerboard assays. The toxicity of the peptide was examined using hemolytic assays.
UNASSIGNED: KW-23 positively affected the standard and resistant Candidal strains (at 5 and 15 μg/mL respectively), exhibiting potent synergistic antimicrobial activity against the standard strain when combined with fluconazole. The effect of the combination was additive against the resistant strain (0.6 μg/mL). Furthermore, the peptide exhibited negligible toxicity on human erythrocytes.
UNASSIGNED: KW-23 and its combination with fluconazole could be a promising candidate for developing anticandidal agents.
UNASSIGNED: A conjugated ultrashort antimicrobial peptide (KW-23) was designed and synthesized. KW-23 was challenged against standard and multidrug-resistant C. albicans alone and in combination with fluconazole using standard antimicrobial and checkerboard assays. The toxicity of the peptide was examined using hemolytic assays.
UNASSIGNED: KW-23 positively affected the standard and resistant Candidal strains (at 5 and 15 μg/mL respectively), exhibiting potent synergistic antimicrobial activity against the standard strain when combined with fluconazole. The effect of the combination was additive against the resistant strain (0.6 μg/mL). Furthermore, the peptide exhibited negligible toxicity on human erythrocytes.
UNASSIGNED: KW-23 and its combination with fluconazole could be a promising candidate for developing anticandidal agents.
摘要：
■由白色念珠菌引起的人类感染很常见，严重程度从相对可治疗的皮肤和粘膜疾病到全身性，致命的侵袭性念珠菌病.真菌感染的治疗受到主要障碍的挑战，包括缺乏有效的治疗选择，现有药物的毒性，和不断升级的抗真菌耐药性。因此，迫切需要开发新类别的抗微生物剂。进行这项研究以研究KW-23肽对单独和与氟康唑组合的白色念珠菌的标准和抗性菌株的作用。
■设计并合成了一种共轭超短抗菌肽（KW-23）。使用标准抗微生物和棋盘测定,KW-23单独和与氟康唑组合对标准和多重耐药性白色念珠菌进行了挑战。使用溶血测定法检查肽的毒性。
■KW-23对标准和抗性念珠菌菌株（分别为5和15μg/mL）产生积极影响，当与氟康唑联合使用时，对标准菌株表现出有效的协同抗菌活性。该组合对抗性菌株(0.6μg/mL)的作用是累加的。此外，该肽对人红细胞的毒性可忽略不计。
■KW-23及其与氟康唑的组合可能是开发抗虫药的有希望的候选药物。
■设计并合成了一种共轭超短抗菌肽（KW-23）。使用标准抗微生物和棋盘测定,KW-23单独和与氟康唑组合对标准和多重耐药性白色念珠菌进行了挑战。使用溶血测定法检查肽的毒性。
■KW-23对标准和抗性念珠菌菌株（分别为5和15μg/mL）产生积极影响，当与氟康唑联合使用时，对标准菌株表现出有效的协同抗菌活性。该组合对抗性菌株(0.6μg/mL)的作用是累加的。此外，该肽对人红细胞的毒性可忽略不计。
■KW-23及其与氟康唑的组合可能是开发抗虫药的有希望的候选药物。
